ZEISS and RIKEN Innovation establish partnership in bioengineering and data management
Synergizing RIKEN's excellence in basic research in bioengineering with ZEISS's expertise in imaging and sensing
ZEISS and RIKEN Innovation Co., Ltd. entered into a strategic collaboration agreement to jointly explore opportunities in aiming to identify projects where the combination of RIKEN’s expertise in bioengineering and image data manipulation and ZEISS’ leadership in optical solutions can accelerate bioengineering innovations and bring about a paradigm change in health care.

Signing of the strategic collaboration agreement: Dr. Stefan Sacré, Head of ZEISS in Japan, Prof. Dr. Hiroshi Matsumoto, President of RIKEN, and Dr. Yoshihiro Aburatani, President RIKEN Innovation (from left).
“We are proud to complement RIKEN’s broad-spectrum and extensive basic research through our expertise in biomedical imaging, which we see as a fundamental ingredient for turning bioengineering into viable healthcare solutions. The success of leading-edge research requires not only groundbreaking ideas but also access and management of advanced scientific equipment. Highest level of instrument availability and advanced image data management are key to efficient R&D”, said Dr. Stefan Sacré, Head of ZEISS in Japan.
RIKEN’s extensive R&D infrastructure and imaging resources provide an excellent base for collaboration between RIKEN and ZEISS. Hiroshi Matsumoto, President of RIKEN, commented, “Today’s Agreement with ZEISS, a corporation which has earned a high level of trust world-wide as a manufacturer of high-precision microscopes and optical instruments, represents a new kind of partnership that does not merely focus on separate research topics. I look forward to an environment in which our partners at ZEISS and researchers at RIKEN engage in free and open discussions, and for RIKEN Innovation to support both organizations in their strategic planning. I expect that this will lead to collaborative research activity of the highest level and the pioneering of new fields.”
Most read news
Organizations

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government - Initial supply of 18 million doses of A(H1N1) influenza vaccine
A Trojan Horse delivery for treating a rare, potentially deadly, blood-clotting disorder - In this possible treatment, platelet blood cells carry an enzyme needed to prevent clots in TTP, while hiding the enzyme from autoantibody neutralization
CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
Novel HCMV compound of AiCuris in phase IIb trial with bone marrow transplant recipients
Basilea receives milestone payment from distribution agreement for Toctino with Almirall
Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
Asia-Pacific continues to drive global healthcare investment, innovation and growth ASEAN - A US$150 billion healthcare market by 2017, says Frost & Sullivan
Pharmacogenomics study finds rare gene variants critical for personalized drug treatment

Cambridge-based Startup Develops World’s Fastest Coronavirus-Killing Antiviral Protection
Evolva shareholders approve all Board proposals in AGM: Green light for Abunda acquisition
Aragen Bioscience, Inc. and CEVEC Sign License Agreement for Human CAP and CAP-T Technology
